



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/552,326

03/20/2006

John Nicholas Staniforth

4781.1073

8789

23280 7590 05/13/2011
Davidson, Davidson & Kappel, LLC
485 7th Avenue
14th Floor
New York, NY 10018

EXAMINER

ALSTRUM ACEVEDO, JAMES HENRY

ART UNIT

PAPER NUMBER

1616

MAIL DATE

DELIVERY MODE

05/13/2011

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/552,326	Applicant(s) STANIFORTH ET AL.	
	Examiner JAMES H. ALSTRUM ACEVEDO	Art Unit 1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 March 2011.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4,6-9,14-31,33-37,39 and 40 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4, 6-9, 14-31, 33-37, and 39-40 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1616

DETAILED ACTION

Claims 1-4, 6-9, 14-31, 33-37, and 39-40 are pending. Applicants amended claim 1. Applicants previously cancelled claims 5, 10-13, 32, and 38. Receipt and consideration of Applicants' amended claim set and remarks/arguments submitted on March 14, 2011 are acknowledged. All rejections/objections not explicitly maintained in the instant office action have been withdrawn per Applicants' claim amendments and/or persuasive arguments.

Election/Restrictions

The species election **is maintained** at this time.

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file. Applicant is granted benefit of the foreign priority document GB 0231612.4 with a filing date of September 15, 2003.

Specification

The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Art Unit: 1616

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Applicant Claims
2. Determining the scope and contents of the prior art.
3. Ascertaining the differences between the prior art and the claims at issue, and resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-4, 6-9, 15-31, 33-37, 39-40 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Edwards et al. (US 2002/0035993) in view of the 1993 Drug Information Handbook (Lacy, C. et al., Lexi-Comp, Inc.: Cleveland, 1993, pp 506-507) (“DIH”), Gupta et al. (US 2002/0006933), Merkus (U.S. Patent No. 5,942,251) and Keller et al. (U.S. Patent No. 6,645,466).

Art Unit: 1616

Applicant Claims

Applicants claim a passive dry powder inhaler (passive DPI) device containing a dry powder formulation comprising apomorphine and a metal stearate, wherein upon actuation of the device a dosing efficiency at 5 microns of at least 70% is achieved.

NOTE: The recited product-by-process limitations recited in Applicants' dependent claims 4, 6-9, and 39-40 are noted, but are not deemed to result in a material structural property of the recited dry powder contained in the claimed passive DPIs.

Determination of the Scope and Content of the Prior Art (MPEP §2141.01)

Edwards teaches inhalable dry powder compositions characterized by **a tap density less than 0.4 g/cc, a mass median aerodynamic diameter (i.e. particle size) ranging from about 1 micron to about 5 microns, and a delivery efficiency of at least 50% that are suitable for administration from single breath-actuated inhalers** (i.e. passive dry powder inhalers) (abstract; ; [0018]; [0022]-[0024]). A variety of active agents may be incorporated into the inhalable particles, such as **L-Dopa**, etc. ([0024], [0055]-[0057]; Example 5: [0199]-[0203]). The inhalable particles are made **by spray drying** ([0158]-[0172]). Suitable commercially available passive DPIs are disclosed in [0080].

The DIH establishes that **L-Dopa is used to treat Parkinson's disease** (pp 506).

Gupta teaches that **apomorphine is suitable for the treatment of Parkinson's disease and has been administered by inhalation administration via the nose** [0041]-[0044]. Gupta teaches **inhalable apomorphine powder formulations** (abstract; [0021]; [0027]; [0047]).

Art Unit: 1616

Merkus teaches that **apomorphine aqueous formulations are unstable**, implying that apomorphine is sensitive to moisture (col. 4, lines 16-17).

Keller teaches inhalable dry powder formulations, wherein the inclusion of magnesium stearate improves the resistance of the active agents contained in the inhalable dry powders to moisture (abstract; col. 4, lines 55-67; col. 45, lines 49-52; col. 6, lines 38-51).

***Ascertainment of the Difference Between Scope the Prior Art and the Claims
(MPEP §2141.012)***

Edwards lacks the teaching of passive dry powder inhalers containing pharmaceutical formulations comprising apomorphine and a metal stearate. These deficiencies are cured by the teachings of Gupta and Keller.

***Finding of Prima Facie Obviousness Rationale and Motivation
(MPEP §2142-2143)***

It would have been *prima facie* obvious to a person of ordinary skill at the time of the instant invention to modify Edwards exemplified L-Dopa formulations to obtain formulations comprising apomorphine, because both L-Dopa and apomorphine are known to be suitable for the treatment of Parkinson's disease (Gupta and Edwards) and both have been known to be formulated in inhalable dry powder formulations (Gupta and Edwards). An ordinary skilled artisan would have been motivated to include magnesium stearate in Edwards formulations modified to contain apomorphine, because apomorphine is known to be unstable in the presence of water (Merkus) and magnesium stearate is known to improve the resistance of water-sensitive active agents in inhalable dry powder formulations (Keller). An ordinary skilled artisan would

Art Unit: 1616

have had a reasonable expectation of combining the teachings of Edwards, Gupta, and Keller, because all these references teach inhalable dry powder formulations and the incorporation of magnesium stearate is known in inhalable dry powder formulations. Furthermore, an ordinary skilled artisan would have been motivated to substitute L-Dopa for apomorphine with a reasonable expectation of success, because both compounds are known to be suitable for treatment of Parkinson's disease and Edwards explicitly teaches that a wide variety may be incorporated into the inhalable particles.

Regarding the reciting dosing efficiencies, Edwards teaches overlapping efficiencies. A prima facie case of obviousness necessarily exists when the prior art range overlaps or touches a claimed range, such as in the instant rejection. MPEP § 2144.05. Similarly, the prior art teaches overlapping tap density values compared to the tap densities recited in claims 34-35 of the instant application. Regarding a tap density range of 0.5 g/cc or greater, it is the Examiner's position that dry powders having a tap density of about 0.4 g/cc as taught by Edwards would be reasonably expected to exhibit similar properties compared to dry powders having a tap density at the lower end of the recited tap density range in dependent claim 36 of the instant application (e.g. tap densities of ~0.50 g/cc would be expected to behave similarly to particle having a tap density of ~0.40 g/cc, such as 0.39 g/cc). Regarding the properties recited in Applicants' dependent claims (e.g. producing a peak blood plasma level within 1-20 minutes of pulmonary inhalation), these properties are considered to necessarily result from the inhalation administration of apomorphine dry powders. Because the aforementioned prior art formulations fairly suggest inhalable apomorphine dry powders comprising a metal stearate and the inhalation administration of these powders, it is concluded that practice of the prior art teachings would

Art Unit: 1616

necessarily result in the same recited properties. Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, because the combined teachings of the prior art is fairly suggestive of the claimed invention.

Response to Arguments

Applicants' arguments filed March 14, 2011 have been fully considered but they are not persuasive. Applicants traverse the instant rejection by attacking the references individually and arguing that (i) Edwards allegedly provides no teaching about the mass of particles having any particular particle size and is suggestive of the targetted delivery of the mass of particles to the oropharynx and larynx, as allegedly evidenced by paragraph [0002] of Edwards; (ii) allegedly the only reason to add magnesium stearate is to tackle the problem of agglomeration which is not a problem faced by Edwards' formulations; (iii) there's no indication in Edwards that a dry powder formulation comprising apomorphine and magnesium stearate will exhibit at least a 70% dosing efficiency at 5 microns; (iv) allegedly the rejection is based upon the "improper" cherry picking of features from the prior art; (v) allegedly the rejection is only based on improper hindsight, because impliedly the only reason to include magnesium stearate is to address problems with agglomeration, which was Applicants' motivation; (vi) Merkus allegedly does not support the notion that apomorphine is unstable in the presence of moisture; and (vii) the rejection is allegedly improper because Keller does not teach a FPF of 70% or more.

The Examiner respectfully finds Applicants' traversal arguments unpersuasive. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on

Art Unit: 1616

combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Argument (i) is based on a misreading of Edwards because at paragraph [0002] Edwards explicitly teaches that the administration of aerosols for systemic delivery is directed towards the targetted delivery of the inhaled therapeutic aerosols to the deep lungs. Contrary to Applicants' assertions the ordinary skilled artisan would not confound delivery to the deep lungs as including the targetted delivery to the oropharynx and larynx. This argument is unpersuasive.

Regarding (ii) and (v), In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Furthermore, the prior art is not required to have the same motivation that inspired Applicants' efforts. As stated in the above rejection, the inclusion of magnesium stearate is to address the art recognized problem of apomorphine stability in the presence of water (*i.e.* moisture).

Regarding (iii), this argument effectively disputes the validity of the **obviousness** rejection for not anticipating the rejection claims. This is unpersuasive, because the instant rejection is not based on an anticipation analysis, but rather an obviousness analysis. Furthermore, the rejection is based upon the combined teachings of the prior art. Thus, to

Art Unit: 1616

compare the teachings of a single reference in isolation of what the other references teach is improper. The argument is unpersuasive.

Regarding (iv), Applicants allege that one would not expect apomorphine to exhibit stability problems due to moisture, because the instability discussed by Merkus was in the context of aqueous compositions. This is found unpersuasive, because the ordinary skilled artisan would expect that water/moisture present in powder formulations would lead to apomorphine instability, although the ordinary skilled artisan may expect the rate at which instability is manifested in a powder formulation to be slower than in the aqueous compositions discussed by Merkus. The rejection is maintained.

Finally, Applicants rely on *Smith Kline Diagnostics v. Helena Laboratories Corp.*, 859 F.2d 878,887 (Fed. Cir. 1988) to support the notion that an obviousness analysis can be based upon the picking and choosing of individual elements from the assorted prior art references. This is found unpersuasive, because the *Smith Kline Diagnostics* decision was published many years before the Supreme Court's decision in *KSR v. Teleflex Inc.*, 82 USPQ2d 1385 (2007) and the cited quotation appears to rely, in part, on a rigid Teaching, Suggestion, Motivation (TSM) test. In *KSR* the Supreme Court explicitly overturned the rigid application of the TSM test, *Id.* at 1398, which appears to be the basis of the cited quotation from the aforementioned Smith Kline Diagnostics decisions; because the sentence following Applicants' quotation explicitly refers to the requirement that a cited reference provide a teaching or suggestion for a particular combination. Moreover, the rejection of record establishes the existence of an art-recognized problem of apomorphine stability in the presence of water/moisture. Reliance on Merkus to demonstrate the recognition of this problem in the art is not impermissible cherry picking,

Art Unit: 1616

because it demonstrates what was commonly known in the art. Furthermore, Merkus was not relied upon for the teaching of any element in the claimed composition, but rather was only relied upon to demonstrate the aforementioned problem. Reliance on Keller to demonstrate that one art-recognized solution to the instability of water-sensitive active agents in inhalable dry powders is the inclusion of magnesium stearate in said formulations is not cherry picking either, because it demonstrates an art recognized solution to a prior art-recognized problem of apomorphine water/moisture instability. Thus, contrary to Applicants' assertions the rejection is not based upon cherry picking and is maintained.

Claim 14 is rejected under 35 U.S.C. 103(a) as being unpatentable over Edwards et al. (US 2002/0035993) in view of the 1993 Drug Information Handbook (Lacy, C. et al., Lexi-Comp, Inc.: Cleveland, 1993, pp 506-507) ("DIH"), Gupta et al. (US 2002/0006933), Merkus (U.S. Patent No. 5,942,251) and Keller et al. (U.S. Patent No. 6,645,466) as applied to claims 1-4, 6-9, 15-31, 33-37, 39-40 above, and further in view of Licalsi et al. (U.S. Patent No. 6,651,655).

Applicant Claims

Applicants claim a passive dry powder inhaler (passive DPI) as described above, wherein the dry powder formulation is pre-metered in one or more foil blisters.

Determination of the Scope and Content of the Prior Art (MPEP §2141.01)

The teachings of Edwards, the DIH, Gupta, Merkus, and Keller are set forth above.

Art Unit: 1616

Licalsi establishes that **foil blisters are conventionally used in the art with multidose dry powder inhalers** to facilitate the delivery of many doses (col. 4, lines 30-32).

***Ascertainment of the Difference Between Scope the Prior Art and the Claims
(MPEP §2141.012)***

Edwards lacks the teaching of a passive DPI with a dry powder formulation pre-metered in foil blisters. This deficiency is cured by the teachings of Licalsi.

***Finding of Prima Facie Obviousness Rationale and Motivation
(MPEP §2142-2143)***

It would have been *prima facie* obvious to a person of ordinary skill at the time of the instant invention to pre-meter doses of a dry powder to be delivered from a DPI in foil blisters, because it is a conventional practice in the art to utilize pre-metered dry powder formulations contained in foil blisters with multidose dry powder inhalers. An ordinary skilled artisan would have been motivated to use foil blisters to contain pre-metered inhalable dry powder formulations for use with a dry powder inhaler and would have had a reasonable expectation of doing so, because foil blisters are conventionally used in the prior art for this purpose (Licalsi). Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, because the combined teachings of the prior art is fairly suggestive of the claimed invention.

Response to Arguments

Applicants' arguments filed March 14, 2011 have been fully considered but they are not persuasive. Applicants traverse the instant rejection by reiterating the previously rebutted arguments and indicating that reliance on Licalsi is also cherry picking. Applicants' arguments are unpersuasive based on the reasons set forth below and the rebuttal of Applicants' arguments set forth above, which is herein incorporated by reference. As Applicants must surely be aware, *KSR* indicated that the selection of a prior art element to be used in the manner for which that element is suitable provides an adequate basis to demonstrate obviousness. In claim 14, Applicants' recite foil blisters as part of passive dry powder inhalers, which impliedly function to contain and store multiple doses of the inhalable dry powder until said powder is to be administered. Licalsi explicitly teachings that that **foil blisters are conventionally used in the art with multidose dry powder inhalers** to facilitate the delivery of many doses (col. 4, lines 30-32). Thus, the recitation of foil blisters in Applicants' claim 14 is merely the use of foil blisters to achieve the function for which foil blisters are conventionally known to be suitable: the storage of one or more inhalable doses in a dry powder inhaler until administration. Consistent with the guidance from *KSR*, it is properly concluded and Licalsi is properly relied upon to demonstrate that the combination of foil blisters with passive dry powder inhalers is obvious. Thus, the rejection does not rely upon improper "cherry picking" and is maintained.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection

Art Unit: 1616

is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-4 and 19-31 remain provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 21, 24, 26, 42, and 44 of copending Application No. 10/552,231 (copending '231). Although the conflicting claims are not identical, they are not patentably distinct from each other because both claim sets recite or claim apomorphine compositions comprising apomorphine and a metal stearate. Independent claim 1 of the instant application is described above. Dependent claim 26 of copending '231 claims a composition for pulmonary inhalation comprising (i) apomorphine in an amount to provide a nominal dose of from about 100 to about 1600 micrograms of apomorphine and (ii) from about 0.15% w/w to about 5% w/w of an additive selected from a group consisting of leucine, magnesium stearate, lecithin, and sodium stearyl fumarate. Both magnesium stearate and sodium stearyl fumarate are metal stearates.

The primary difference between dependent claim 26 of copending '231 and the claims of the instant application is that dependent claim 26 of copending '231 does not recite that the composition is contained within a passive dry powder inhaler (i.e. a breath-actuated DPI) or that

Art Unit: 1616

the apomorphine composition has a dosing efficiency at 5 microns of at least 70%. Dependent claims 21 and 24 of copending '231 establish that it is an obvious modification of the claimed composition of copending '231 to formulate the composition where the apomorphine is in the form of particles having a MMAD of 5 microns or less. It is the Examiner's position that the apomorphine particulate composition comprising apomorphine and a metal stearate and having a MMAD of 5 microns or less would necessarily exhibit the recited dosing efficiency. Dependent claims 42 and 44 of copending '231 establish that an obvious modification of the claims of copending '231 would be to place said compositions within a passive DPI (i.e. a breath-actuated inhaler device). Therefore, a person of ordinary skill in the art at the time of the instant invention would have found claims 1-4 and 6-7 *prima facie* obvious claims 1, 21, 24, 26, 42, and 44 of copending Application No. 10/552,231 (copending '231).

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Response to Arguments

Applicants arguments/remarks submitted on March 14, 2011 did not traverse the instant rejection and indicated that Applicants would consider filing a terminal disclaimer upon the identification of allowable subject matter. The instant rejection is maintained.

Claims 1-4 and 19-31 remain provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 and 99-100 of

Art Unit: 1616

copending Application No. 12/459,686 (copending '686) in view of Staniforth et al. (US 2004/0204439).

Independent claim 1 of the instant application is described above. Dependent claim 100 of copending '686 claims a composition for pulmonary inhalation comprising (i) apomorphine in an amount to provide a nominal dose of from about 100 to about 600 micrograms of apomorphine, (ii) from about 0.1% w/w to about 10% w/w of a carrier material, and (iii) a force control agent selected from a group consisting of leucine, magnesium stearate, lecithin, and sodium stearyl fumarate. Both magnesium stearate and sodium stearyl fumarate are metal stearates.

The primary difference between dependent claim 100 of copending '686 and the claims of the instant application is that dependent claim 100 of copending '686 does not recite that the composition is contained within a passive dry powder inhaler (i.e. a breath-actuated DPI) or that the apomorphine composition has a dosing efficiency at 5 microns of at least 70%. These deficiencies are cured by the teachings of Staniforth set forth above. Thus, it would be a *prima facie* obvious modification of claim 100 of copending '686 in view of the teachings of Staniforth to place the composition of claim 100 of copending '686 within a passive dry powder inhaler and to use particulate apomorphine having a dosing efficiency at 5 microns of at least 70%. Therefore, a person of ordinary skill in the art at the time of the instant invention would have found claims 1-4 and 19-32 *prima facie* obvious claims 1, 21, 24, 26, 42, and 44 of copending Application No. 10/552,231 (copending '231).

This is a provisional obviousness-type double patenting rejection.

Art Unit: 1616

Response to Arguments

Applicants arguments/remarks submitted on March 14, 2011 did not traverse the instant rejection and indicated that Applicants would consider filing a terminal disclaimer upon the identification of allowable subject matter. The instant rejection is maintained.

Conclusion

Claims 1-4, 6-9, 14-31, 33-37, and 39-40 are rejected. No claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James H. Alstrum-Acevedo whose telephone number is (571) 272-5548. The examiner can normally be reached on M-F, ~10:00-6:00 and Saturdays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571) 272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/JAMES H. ALSTRUM-ACEVEDO/
Primary Examiner, Art Unit 1616
Technology Center 1600

J.H. Alstrum-Acevedo, Ph.D.